Bank of America Securities: Upgraded Hansoh Pharma (03692) rating to buy, target price raised to HKD 20.8.

Zhitong FinanceJun 5 22:26

Kangfang Biology (09926.HK): Evosimab has been approved domestically, and K-drug head-to-head success is expected to become the next generation of IO cornerstone drugs

中金公司Jun 5 06:26

Bocom Intl reaffirms their buy rating for Akeso (09926) with a target price of HKD 70.

Zhitong FinanceJun 4 20:17

Bocom Intl reaffirms their buy rating for Akeso (09926) with a target price of HKD 70.

Zhitong FinanceJun 3 22:18

Ali Health (0241.HK): FY2024 results exceeded expectations, gross margin steadily increased, and fulfillment fee rates were significantly optimized

海通國際Jun 3 21:51

Kangfang Biology (9926.HK): The world's first head-to-head KEYTRUDA single drug phase III obtained excellent PFS results and reaffirmed the purchase rating

交銀國際Jun 3 03:11

Citi: Maintaining Ali Health's (00241) “Buy” Rating Target Price Raised to HK$4.2

Zhitong FinanceJun 3 00:50

BOC International: Reiterates Kangfang Biotech's (09926) “Buy” Rating Target Price of HK$70

Zhitong FinanceJun 2 21:12

Research Nuggets | CICC: Maintaining Ali Health's Target Price of HK$4.2 and Upgrading “Outperform the Industry” Rating

Gelonghui FinanceJun 2 21:04

Kangfang Biology (09926.HK): AK112 head-to-head K drug has achieved excellent efficacy and is expected to become a new cornerstone of immunotherapy

國信證券Jun 2 18:16

Analysts' Opinions Are Mixed on These Healthcare Stocks: Carl Zeiss Meditec (GB:0DHC), Akeso, Inc. (HK:9926) and Almirall (GB:0O9B)

TipRanksJun 1 04:07

Kangfang Biology (9926.HK) Company Follow-up Review: Evosil defeated K Pharmaceuticals head-to-head and ushered in the harvest period

國泰君安May 31 05:26

Cinda Biotech (1801.HK): Multiple Products Showcased at ASCO Conference IBI112 Reached Phase 3 Clinical End-point

中信建投證券May 30 22:06

CICC: Maintaining Ali Health's (00241) “Outperform the Industry” rating target price of HK$4.2

Zhitong FinanceMay 30 20:13

Kangfang Biotech (9926.HK): AK112's head-to-head K drug successfully met expectations and boosted stock price rebound

浦銀國際May 30 11:00

Lyon: Maintaining Ali Health's (00241) “Buy” Rating Target Price Raised to HK$4.5

Zhitong FinanceMay 29 00:39

UBS: Reiterates the increase in the target price of the “buy” rating of CSPC Group (01093) to HK$10.1

Zhitong FinanceMay 28 21:15

CSPC Group (1093.HK): Pharmaceutical performance exceeds expectations, innovation enters the harvest period

國泰君安May 28 11:00

CSPC PHARMACEUTICAL(1093.HK):ACCELERATING GROWTH IN FINISHED DRUG SALES

招银国际May 28 06:16

Nomura Adjusts CSPC Pharmaceutical's Price Target to HK$10.07 From HK$9.41, Keeps at Buy

MT NewswiresMay 28 03:03